ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $357,052 | -16.6% | 17,133 | -4.2% | 0.10% | -13.6% |
| Q2 2023 | $428,298 | +12.3% | 17,883 | -11.8% | 0.12% | +7.3% |
| Q1 2023 | $381,387 | +18.2% | 20,265 | 0.0% | 0.11% | +6.8% |
| Q4 2022 | $322,619 | +23.1% | 20,265 | +26.5% | 0.10% | +22.6% |
| Q3 2022 | $262,000 | +12.4% | 16,015 | -3.0% | 0.08% | +21.7% |
| Q2 2022 | $233,000 | -41.8% | 16,515 | 0.0% | 0.07% | -12.7% |
| Q1 2022 | $400,000 | +3.9% | 16,515 | 0.0% | 0.08% | -2.5% |
| Q4 2021 | $385,000 | +40.5% | 16,515 | 0.0% | 0.08% | +42.1% |
| Q3 2021 | $274,000 | -22.8% | 16,515 | +13.6% | 0.06% | -21.9% |
| Q2 2021 | $355,000 | +71.5% | 14,535 | +276.1% | 0.07% | +32.7% |
| Q4 2020 | $207,000 | -33.0% | 3,865 | -39.3% | 0.06% | -48.6% |
| Q2 2020 | $309,000 | +53.7% | 6,365 | +64.7% | 0.11% | +25.9% |
| Q1 2020 | $201,000 | -63.5% | 3,865 | -70.0% | 0.08% | -55.5% |
| Q4 2019 | $550,000 | – | 12,865 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |